The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
TCT 2021 | Cytogenetic risk stratification in FLT3-mt NPM1-negative AML undergoing alloSCT in remission
Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, outlines the role of cytogenetic risk stratification in FLT3-mutated NPM1-negative patients with AML undergoing allogeneic stem cell transplantation (alloSCT) in remission. In these patients, cytogenetic risk is significantly associated with outcome and therefore an important prognosticator in FLT3-mutated, NPM1-negative AML patients undergoing alloSCT. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.
